JMP Securities Thinks Cormedix’s Stock is Going to Recover

JMP Securities analyst Jason Butler reiterated a Buy rating on Cormedix (CRMDResearch Report) today and set a price target of $19.00. The company’s shares closed last Monday at $4.85, close to its 52-week low of $3.65.

According to, Butler has 0 stars on 0-5 stars ranking scale with an average return of -4.4% and a 37.5% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, ACADIA Pharmaceuticals, and Aquestive Therapeutics.

Currently, the analyst consensus on Cormedix is a Moderate Buy with an average price target of $19.00.

See the top stocks recommended by analysts >>

Cormedix’s market cap is currently $153.1M and has a P/E ratio of -5.48.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.

Read More on CRMD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More